Shane W. O’Brien

1.4k total citations
14 papers, 602 citations indexed

About

Shane W. O’Brien is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Shane W. O’Brien has authored 14 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Shane W. O’Brien's work include Ubiquitin and proteasome pathways (3 papers), Cancer-related gene regulation (3 papers) and Epigenetics and DNA Methylation (2 papers). Shane W. O’Brien is often cited by papers focused on Ubiquitin and proteasome pathways (3 papers), Cancer-related gene regulation (3 papers) and Epigenetics and DNA Methylation (2 papers). Shane W. O’Brien collaborates with scholars based in United States, Russia and Japan. Shane W. O’Brien's co-authors include Denise C. Connolly, Samuel Litwin, Rashid Gabbasov, Erica A. Golemis, James S. Duncan, Alison Kurimchak, Jonathan Chernoff, Lauren S. Fink, Kelly Duncan and Yuesheng Li and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Shane W. O’Brien

14 papers receiving 598 citations

Peers

Shane W. O’Brien
Vered Givant-Horwitz Norway
Ana Slipicevic Norway
Yangxin Fu Canada
Sergey Karakashev United States
Diana E. Lamendola United States
Timothy A. Yap United Kingdom
Debottam Sinha Australia
Maureen M. Hattersley United States
Hye‐Kyung Jeon South Korea
Jessica A. Gasser United States
Vered Givant-Horwitz Norway
Shane W. O’Brien
Citations per year, relative to Shane W. O’Brien Shane W. O’Brien (= 1×) peers Vered Givant-Horwitz

Countries citing papers authored by Shane W. O’Brien

Since Specialization
Citations

This map shows the geographic impact of Shane W. O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shane W. O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shane W. O’Brien more than expected).

Fields of papers citing papers by Shane W. O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shane W. O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shane W. O’Brien. The network helps show where Shane W. O’Brien may publish in the future.

Co-authorship network of co-authors of Shane W. O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Shane W. O’Brien. A scholar is included among the top collaborators of Shane W. O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shane W. O’Brien. Shane W. O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
O’Brien, Shane W., Christine Thompson, Boris G. Wilson, et al.. (2023). Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer. 23(1). 775–775. 16 indexed citations
2.
Fedoriw, Andrew, Leilei Shi, Shane W. O’Brien, et al.. (2022). Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses. Cancer Immunology Research. 10(4). 420–436. 26 indexed citations
3.
Kurimchak, Alison, Valerie L. Sodi, Nishi Srivastava, et al.. (2020). Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. Science Signaling. 13(619). 19 indexed citations
4.
Gabbasov, Rashid, Shane W. O’Brien, John J. Krais, et al.. (2019). Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biology & Therapy. 20(7). 1035–1045. 22 indexed citations
5.
Patel, Niravkumar R., Aleksandr Piroyan, Srinivas Ganta, et al.. (2018). In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers. Cancer Biology & Therapy. 19(7). 554–564. 34 indexed citations
6.
Gabbasov, Rashid, Caitlin G. Howe, Shane W. O’Brien, et al.. (2018). NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene. 37(35). 4854–4870. 22 indexed citations
7.
Perales‐Puchalt, Alfredo, Nikolaos Svoronos, Melanie R. Rutkowski, et al.. (2016). Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clinical Cancer Research. 23(2). 441–453. 82 indexed citations
8.
Kurimchak, Alison, Claude Shelton, Kelly Duncan, et al.. (2016). Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Reports. 16(5). 1273–1286. 143 indexed citations
9.
Gritsina, Galina, Fang Xiao, Shane W. O’Brien, et al.. (2015). Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Molecular Cancer Therapeutics. 14(4). 1035–1047. 84 indexed citations
10.
Gritsina, Galina, Xiao Fang, Shane W. O’Brien, et al.. (2014). Abstract 1113: Targeting the JAK2/STAT3 pathway in ovarian cancer. Cancer Research. 74(19_Supplement). 1113–1113. 1 indexed citations
11.
Liu, Hanqing, Ilya G. Serebriiskii, Shane W. O’Brien, et al.. (2013). Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer. Clinical Cancer Research. 19(18). 5053–5067. 41 indexed citations
12.
Klein–Szanto, Andres J., Harsh B. Pathak, Hua Xiang, et al.. (2013). Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 33(5). 539–549. 87 indexed citations
13.
14.
Anderes, Kenna, Nicole Streiner, May Omori, et al.. (2010). Effect of CX-4945, a selective bioavailable small molecule inhibitor of protein kinase CK2, on gemcitabine antitumor activity in A2780 ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). e13522–e13522. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vered Givant-Horwitz Breakdown of academic impact, for papers by Ana Slipicevic Breakdown of academic impact, for papers by Yangxin Fu Breakdown of academic impact, for papers by Sergey Karakashev Breakdown of academic impact, for papers by Diana E. Lamendola Breakdown of academic impact, for papers by Timothy A. Yap Breakdown of academic impact, for papers by Debottam Sinha Breakdown of academic impact, for papers by Maureen M. Hattersley Breakdown of academic impact, for papers by Hye‐Kyung Jeon Breakdown of academic impact, for papers by Jessica A. Gasser
Rankless by CCL
2026